中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.04 seconds)

    TREATMENT OF CONDITIONS INVOLVING DEMYELINATION
    2.
    发明申请
    TREATMENT OF CONDITIONS INVOLVING DEMYELINATION 审中-公开
    治疗涉及血色素沉着的病症

    公开(公告)号：WO2007064882A2

    公开(公告)日：2007-06-07

    申请号：PCT/US2006/045993

    申请日：2006-12-01

    Applicant: BIOGEN IDEC MA INC. ,  MI, Sha ,  PEPINSKY, R., Blake ,  MCCOY, John

    Inventor： MI, Sha ,  PEPINSKY, R., Blake ,  MCCOY, John

    IPC: A61K39/395

    CPC classification number: C07K16/28 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0393 ,  A61K2039/505 ,  C07K14/4702 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12N15/8509

    Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrcoyte progenitor cells with an ErbB2 binding agent.

    Abstract translation: 本发明提供了通过施用Sp35拮抗剂治疗涉及脱髓鞘和髓鞘形成障碍包括多发性硬化的疾病，障碍或损伤的方法。 另外的方法包括抑制Sp35多肽与ErbB2多肽结合的方法和通过使少突胶质细胞与有效量的包含本发明的Sp35拮抗剂的组合物接触来增加ErbB2磷酸化的方法。 本发明进一步的实施方案包括抑制Sp35多肽与ErbB2的结合，增加ErbB2磷酸化和促进少突胶质细胞分化的方法，包括使少突胶质细胞或少突胶质祖细胞与ErbB2结合剂接触。

    COMPOSITIONS COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF
    3.
    发明申请
    COMPOSITIONS COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF 审中-公开
    包含抗体或其片段的组合物

    公开(公告)号：WO2010005570A2

    公开(公告)日：2010-01-14

    申请号：PCT/US2009/003999

    申请日：2009-07-09

    Applicant: BIOGEN IDEC MA INC. ,  MI, Sha ,  PEPINSKY, R., Blake

    Inventor： MI, Sha ,  PEPINSKY, R., Blake

    IPC: C07K16/28 ,  A61K39/395

    CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6849 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01

    Abstract: Endogenous LINGO-I is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-I function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-I, and methods of using such antibodies as antagonists of endogenous LINGO-I function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.

    Abstract translation: 内源性LINGO-I是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节物。 阻断内源性LINGO-1功能的分子，例如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供了特异于LINGO-1的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供了特异性杂交瘤和噬菌体文库衍生的单克隆抗体，编码这些抗体的核酸以及包含这些抗体的载体和宿主细胞。 本发明进一步提供了促进脊椎动物中少突胶质细胞存活和髓鞘形成的方法，包括向需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体。

    SP35 ANTIBODIES AND USES THEREOF
    4.
    发明申请
    SP35 ANTIBODIES AND USES THEREOF 审中-公开
    SP35抗体及其用途

    公开(公告)号：WO2008086006A2

    公开(公告)日：2008-07-17

    申请号：PCT/US2008/000316

    申请日：2008-01-09

    Applicant: BIOGEN IDEC MA INC. ,  MI, Sha ,  PEPINSKY, R., Blake ,  SHAO, Zhaohui ,  GARBER, Ellen, A. ,  MIKLASZ, Steven, D.

    Inventor： MI, Sha ,  PEPINSKY, R., Blake ,  SHAO, Zhaohui ,  GARBER, Ellen, A. ,  MIKLASZ, Steven, D.

    IPC: A61K39/395

    CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

    Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。

    USE OF DR6 AND P75 ANTAGONISTS TO PROMOTE SURVIVAL OF CELLS OF THE NERVOUS SYSTEM
    5.
    发明申请
    USE OF DR6 AND P75 ANTAGONISTS TO PROMOTE SURVIVAL OF CELLS OF THE NERVOUS SYSTEM 审中-公开

    公开(公告)号：WO2010062904A3

    公开(公告)日：2010-06-03

    申请号：PCT/US2009/065755

    申请日：2009-11-24

    Applicant: BIOGEN IDEC MA INC. ,  MI, Sha ,  RHODES, Kenneth, J. ,  PEPINSKY, R., Blake

    Inventor： MI, Sha ,  RHODES, Kenneth, J. ,  PEPINSKY, R., Blake

    IPC: A61K39/395

    Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

    OLIGODENDROCYTE-MYELIN GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    10.
    发明申请
    OLIGODENDROCYTE-MYELIN GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
    OLIGODENDROCYTE-MYELIN GLYCOPROTEIN组合物及其使用方法

    公开(公告)号：WO2007050866A2

    公开(公告)日：2007-05-03

    申请号：PCT/US2006/041966

    申请日：2006-10-27

    Applicant: BIOGEN IDEC MA INC. ,  MI, Sha ,  PEPINSKY, Blake, R.

    Inventor： MI, Sha ,  PEPINSKY, Blake, R.

    IPC: A61K38/17

    CPC classification number: A61K38/17 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356 ,  C07K14/70503 ,  C12N15/8509

    Abstract: The present invention is based on the discovery that oligodendrocyte-myelin glycoprotein (OMgp), which is expressed by oligodendrocytes and CNS myelin, negatively regulates oligodendrocyte and neuronal differentiation and survival. Based on these discoveries, the invention relates generally to methods of promoting neuronal and oligodendrocyte survival and differentiation by administration of an OMgp anatagonist. Additionally, the invention generally relates to methods of treating various diseases, disorders or injuries associated with demyelination, dysmyelination, oligodendrocyte/neuronal cell death, axonal injury and/or differentiation by the administration of an OMgp antagonist.

    Abstract translation: 本发明是基于由少突胶质细胞和CNS髓鞘表达的少突胶质母细胞髓磷脂糖蛋白（OMgp）负调节少突胶质细胞和神经元分化和存活的发现。 基于这些发现，本发明一般涉及通过施用OMGP拮抗剂来促进神经元和少突胶质细胞存活和分化的方法。 此外，本发明一般涉及治疗与脱髓鞘相关的各种疾病，病症或损伤，通过施用OMgp拮抗剂的脱髓鞘，少突胶质细胞/神经元细胞死亡，轴索损伤和/或分化的方法。

Patent Agency Ranking